For its first fiscal quarter (ending March 31), Editas Medicine Inc (NASDAQ: EDIT) has reported E.P.S. of $-0.76 compared to $-0.71 a year ago. This result fell short of the consensus estimate of $-0.63 by $-0.13. For the latest four quarters through March 31, E.P.S. were $-2.10 compared to $-3.18 a year ago.
Recent Price Action
On 5/8/24, Editas Medicine Inc (NASDAQ: EDIT) stock suffered a major decline of -11.4%, closing at $5.03. Moreover, this decline was accompanied by exceptionally high trading volume at 220% of normal. Relative to the market the stock has been weak over the last nine months and has declined -3.4% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, EDIT is expected to continue to be Value Creation neutral.
Editas Medicine has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Editas Medicine has a poor Appreciation Score of 22 and a poor Power Rating of 15, triggering the Lowest Value Trend Rating.
Rating Review
In light of this new information and highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment